Exchange: NASDAQ·Updated 07:44 PM EDT
ANAB logo

ANAB AnaptysBio Inc

$45.76
$0.26
(0.56%)
Today
Closed $45.95
$0.19
(0.41%)
After Hours
Reported EarningsSep 21
Mkt Cap$1.37B
Vol495,669.00

About ANAB

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
56

Bullish Sentiment

How do you feel about ANAB?

StocktwitsEarnings
$ANAB Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $5.11 up 481.34% YoY • Reported revenue of $27.49M up 23.50% YoY • AnaptysBio continues to expect to achieve $390M in annualized Jemperli royalties payable to the company as early as 2029 at GSKs peak monotherapy sales guidance of $2.7B.
1

Advertisement|Remove ads.